# ARTEMIDE-01 (NCT04995523)

> A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04995523
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small-Cell Lung Carcinoma
- Interventions: AZD2936
- Enrollment: 212
- Primary outcome: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
- Primary outcome: Rate of rilvegostomig discontinuation due to toxicity
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=artemide-01-nct04995523

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04995523", "email": "<work email>"}; the inbox owner confirms by the emailed link.